Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment.
Browsing: weight loss treatment
Novo Nordisk edges past Tesla in market value on successful obesity pill trial. Danish company’s shares soar.